Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 26 sep 2016 - 02:14

Statutaire naam Galapagos NV

Titel Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease

Bericht Conference call 26 September at 14.00 CET/8 AM ET, +32 2 400 6926, code 8889838 Mechelen, Belgium; 26 September 2016 02.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports that Dr Severine Vermeire, principal investigator of the FITZROY Phase 2 study with investigational agent filgotinib in Crohn's disease, will present endoscopic and other key findings from the study in an oral session during United European Gastroenterology Week (UEG Week) in Vienna, Oct. 15 - 19, 2016. The abstract for the talk is available online at www.ueg.eu/week/.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201609260000000001_Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn.pdf (opens in a new window)

201609260000000001_NL Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn.pdf (opens in a new window)

Datum laatste update: 22 december 2025